Cancel-Tassin G - Search Results

1

Different Pigmentation Risk Loci for High-Risk Monosomy 3 and Low-Risk Disomy 3 Uveal Melanomas.

Mobuchon L, Derrien AC, Houy A, Verrier T, Pierron G, Cassoux N, Milder M, Deleuze JF, Boland A, Scelo G, Cancel-Tassin G, Cussenot O, Rodrigues M, Noirel J, Machiela MJ, Stern MH. Mobuchon L, et al. J Natl Cancer Inst. 2022 Feb 7;114(2):302-309. doi: 10.1093/jnci/djab167. J Natl Cancer Inst. 2022. PMID: 34424336 Free PMC article.

2

Microsatellite instability in urothelial carcinoma of the upper urinary tract.

Amira N, Rivet J, Soliman H, Cancel-Tassin G, Le Duc A, Janin A, Cussenot O. Amira N, et al. J Urol. 2003 Oct;170(4 Pt 1):1151-4. doi: 10.1097/01.ju.0000086551.22844.cd. J Urol. 2003. PMID: 14501713

3

[Genetic susceptibility to prostate cancer].

Cussenot O, Cancel-Tassin G. Cussenot O, et al. Med Sci (Paris). 2004 May;20(5):562-8. doi: 10.1051/medsci/2004205562. Med Sci (Paris). 2004. PMID: 15190476 Free article. Review. French.

4

Expression in bladder transitional cell carcinoma by real-time quantitative reverse transcription polymerase chain reaction array of 65 genes at the tumor suppressor locus 9q34.1-2: identification of 5 candidates tumor suppressor genes.

Amira N, Cancel-Tassin G, Bernardini S, Cochand-Priollet B, Bittard H, Mangin P, Fournier G, Latil A, Cussenot O. Amira N, et al. Int J Cancer. 2004 Sep 10;111(4):539-42. doi: 10.1002/ijc.20283. Int J Cancer. 2004. PMID: 15239131 Free article.

5

Prostate cancer genetics.

Cancel-Tassin G, Cussenot O. Cancel-Tassin G, et al. Minerva Urol Nefrol. 2005 Dec;57(4):289-300. Minerva Urol Nefrol. 2005. PMID: 16247350 Review.

6

Genetic susceptibility to prostate cancer.

Cancel-Tassin G, Cussenot O. Cancel-Tassin G, et al. BJU Int. 2005 Dec;96(9):1380-5. doi: 10.1111/j.1464-410X.2005.05836.x. BJU Int. 2005. PMID: 16287462 Review. No abstract available.

7

Low penetrance genetic susceptibility to kidney cancer.

Thibault F, Cancel-Tassin G, Cussenot O. Thibault F, et al. BJU Int. 2006 Oct;98(4):735-8. doi: 10.1111/j.1464-410X.2006.06351.x. BJU Int. 2006. PMID: 16978268 Review. No abstract available.

8

Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.

Cussenot O, Azzouzi AR, Nicolaiew N, Mangin P, Cormier L, Fournier G, Valeri A, Cancel-Tassin G. Cussenot O, et al. Eur Urol. 2007 Oct;52(4):1082-7. doi: 10.1016/j.eururo.2007.04.008. Epub 2007 Apr 13. Eur Urol. 2007. PMID: 17448593

9

Multiple loci identified in a genome-wide association study of prostate cancer.

Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Thomas G, et al. Nat Genet. 2008 Mar;40(3):310-5. doi: 10.1038/ng.91. Epub 2008 Feb 10. Nat Genet. 2008. PMID: 18264096

10

Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.

Cussenot O, Azzouzi AR, Bantsimba-Malanda G, Gaffory C, Mangin P, Cormier L, Fournier G, Valeri A, Jouffe L, Roupret M, Fromont G, Sibony M, Comperat E, Cancel-Tassin G. Cussenot O, et al. Clin Cancer Res. 2008 Sep 1;14(17):5635-9. doi: 10.1158/1078-0432.CCR-07-4999. Clin Cancer Res. 2008. PMID: 18765558

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

169 results

Search Page